CEO
Vividion Therapeutics
Vividion Therapeutics provides a covalent‑first chemoproteomics platform that maps reactive cysteine sites across the human proteome and screens them with a >50,000 electrophilic fragment library using high‑throughput mass‑spectrometry. The workflow identifies shallow or cryptic pockets suitable for irreversible small‑molecule inhibitors, enabling pharmaceutical and biotech R&D programs to develop selective drugs against previously undruggable targets.
Updated 6 months ago
Funding
Raised to date
$135MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
A large proportion of disease‑associated proteins lack suitable binding pockets for conventional small‑molecule drugs, leaving many cancers and immune disorders without effective therapeutic options. Traditional discovery methods focus on deep active sites and often cannot generate selective, high‑affinity ligands for these “undruggable” targets.
Solution
Vividion Therapeutics operates a covalent‑first chemoproteomics platform that systematically maps reactive sites across the human proteome and matches them with a proprietary library of electrophilic fragments. By using high‑throughput mass‑spectrometry screening, the platform identifies shallow or cryptic pockets—particularly cysteine residues—that can form irreversible, high‑selectivity bonds with small molecules. The resulting covalent inhibitors are advanced through iterative chemistry and biological validation, producing drug candidates that address targets previously considered inaccessible. This approach expands the addressable target space for small‑molecule therapeutics and accelerates the progression of novel agents into clinical evaluation.
Target Audience
Pharmaceutical and biotechnology R&D organizations seeking to target previously undruggable proteins, as well as academic drug‑discovery programs requiring a proteome‑wide covalent screening capability.
Features
- Custom library of >50,000 covalent fragments engineered to remain inert until they encounter a complementary protein surface, emphasizing reactive cysteines.
- High‑resolution, high‑throughput mass‑spectrometry chemoproteomics workflow that profiles thousands of proteins in native cellular contexts in a single run.
- Integrated data portal that aggregates ~250,000 proteome‑wide reactivity data points per day, overlaying public genetics and structural databases to prioritize druggable pockets.
- Covalent‑first design strategy that enables irreversible binding to shallow or cryptic sites, delivering potency and selectivity unattainable with non‑covalent chemistry.
- Iterative learning loop linking fragment hits to medicinal chemistry optimization, generating lead compounds ready for preclinical and clinical development.
- Platform versatility supporting multiple modalities, including allosteric inhibition, protein‑protein interaction disruption, and targeted protein degradation.
- Proven pipeline with several candidates already in Phase I/II clinical trials, demonstrating translational capability of the discovery engine.